Open Label,Single Arm,Exploratory Study to Evaluate the Safety,Tolerability,Compliance and MOA,of QBKPN SSI in Subjects With 2 or More Second Primary Pre-invasive/Invasive Adenocarcinoma Following Surgical Resection of Stage I NSCLC
Phase of Trial: Phase II
Latest Information Update: 25 Feb 2016
Price : $35 *
At a glance
- Drugs QBKPN (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Qu Biologics
- 18 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Feb 2015 Status changed from not yet recruiting to recruiting, according to a Qu Biologics media release.
- 18 Oct 2014 New trial record